FinnCap restated their corporate rating on shares of Oncimmune (LON:ONC) in a report issued on Wednesday morning, ThisIsMoney.Co.Uk reports.

Shares of ONC stock traded up GBX 4.50 ($0.06) on Wednesday, hitting GBX 36 ($0.47). 6,643,033 shares of the stock traded hands, compared to its average volume of 33,554. Oncimmune has a twelve month low of GBX 30 ($0.39) and a twelve month high of GBX 115 ($1.51). The firm’s 50-day moving average price is GBX 36.46 and its two-hundred day moving average price is GBX 65.25. The stock has a market capitalization of $22.77 million and a PE ratio of -2.77.

Oncimmune Company Profile

Oncimmune Holdings Plc, an early cancer detection company, develops and commercializes products to diagnose cancer in the United Kingdom and North America. The company engages in the development of autoantibody based platform to allow cancer detection to a range of solid cancer tumor types. It offers EarlyCDT-Lung, a blood test, which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy.

Recommended Story: How Do You Make Money With Penny Stocks?

Receive News & Ratings for Oncimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncimmune and related companies with MarketBeat.com's FREE daily email newsletter.